Aesthetic neurotoxins remain the most performed physician-administered aesthetic procedure category worldwide, and published industry analyses project the broader medical-aesthetics market to exceed €30 billion by 2030.
Europe presents a distinctive structure: strong physician channels, a mature regulatory framework and growing patient demand — yet a concentrated competitive landscape with limited comparability-based participation to date.
The EMA-aligned comparability pathway offers a defined, evidence-based route to market. For developers, comparability-first programs can be capital-efficient relative to de novo innovation, while offering payers, physicians and patients the prospect of broader access.
ObNowa Pharma's neurotoxin portfolio comprises a bio-comparable program designed around established performance standards and a bio-better program exploring differentiated characteristics for medical aesthetics. Both programs are investigational and in development.
This article reflects ObNowa Pharma's perspective on market structure and does not constitute investment advice or a claim of product approval.
Development status — all programs presented are currently in research and development. Potential indications and applications reflect development objectives and do not represent established efficacy, safety or regulatory approval.